FSH and Sertoli Cell Biomarkers Accurately Distinguish Hypogonadotropic Hypogonadism From Self-limited Delayed Puberty
The Journal of Clinical Endocrinology & Metabolism · 16.09.2025 · 110 (10) · e3203-e3214
DOI: 10.1210/clinem/dgaf062 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 11.02.2025. Verfasst von Sebastián Castro und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigaciones Endocrinológicas "Dr. César Bergadá" (CEDIE), CONICET-FEI-División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, …. Hauptthemen laut MEDLINE: Hypogonadism, Sertoli Cells, Puberty, Delayed, Follicle Stimulating Hormone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina, Fondo para la Investigación Científica y Tecnológica, NICHD NIH HHS.
Abstract (Originalsprache)
Context
Delayed puberty is a frequent complaint in males. The differential diagnosis between self-limited delayed puberty (SLDP) and congenital hypogonadotropic hypogonadism (CHH) is challenging. Commonly used endocrine tests, focusing on stimulated levels of LH or testosterone, are not satisfactory in making a diagnosis. Because FSH action on Sertoli cells results in testis enlargement and anti-Müllerian hormone (AMH) and inhibin B increased secretion, and the FSH-Sertoli cell axis function is detectable during normal childhood and early puberty, we tested whether the assessment of serum FSH, AMH, and inhibin B would be informative to distinguish between SLDP and CHH.
Design
We performed a prospective, nested case-control study in a cohort of male adolescents presenting with delayed puberty, comparing baseline serum reproductive hormone levels to identify predictive biomarkers of CHH, after having followed all participants prospectively until a final diagnosis was ascertained based on gold-standard criteria (age 18 years or ≥4 years after testis volume reached 4 mL).
Results
Of 65 participants who completed follow-up, 33 had a final diagnosis of SLDP and 32 of CHH. Serum FSH, AMH, and inhibin B showed better diagnostic efficiency than LH and testosterone for these differential diagnoses. FSH (IU/L)×inhibin B (pg/mL) < 92 and FSH (IU/L)×AMH (pmol/L) < 537 showed high sensitivity (>93%), specificity (≥92%), predictive values (>92%), and positive likelihood ratio (>12) for CHH. The diagnostic performance remained 89.7% and 88.2% for FSH × inhibin B and FSH × AMH, respectively, when analyzed in patients without red flags (micropenis, cryptorchidism, and/or microorchidism).
Conclusion
Serum FSH combined with inhibin B or AMH is highly predictive to accurately distinguish between SLDP and CHH in adolescent males.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Investigaciones Endocrinológicas "Dr. César Bergadá" (CEDIE), CONICET-FEI-División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, C1425EFD Buenos Aires, Argentina.
- Unidad de Medicina Traslacional, Hospital de Niños Ricardo Gutiérrez, C1425EFD Buenos Aires, Argentina.
- División de Endocrinología Pediátrica, Hospital Italiano de Buenos Aires, C1199ABB Buenos Aires, Argentina.
- Division of Endocrinology, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.
- Instituto de Investigaciones Materno Infantil (IDIM), Universidad de Chile, Santiago 8320000, Chile.
ORCID-Profile: Sebastián Castro, Lourdes Correa Brito, María Gabriela Ballerini, Andrea Josefina Arcari, Guillermo F Alonso, Yee-Ming Chan, Fernando Cassorla, Rodolfo A Rey, Romina P Grinspon
Förderung
- Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina
- Fondo para la Investigación Científica y Tecnológica
- NICHD NIH HHS
- National Institute for Child Health and Human Development
- National Institutes of Health, USA
- Agencia Nacional de Promoción de la Ciencia y Tecnología, Argentina
Zitieren
APA
Castro, S., Correa Brito, L., Bedecarrás, P., Ballerini, M. G., Sansó, G., Keselman, A., Cassinelli, H., Arcari, A. J., Alonso, G. F., Chan, Y. M., He, W., Ropelato, M. G., Bergadá, I., Cassorla, F., Rey, R. A., & Grinspon, R. P. (2025). FSH and Sertoli Cell Biomarkers Accurately Distinguish Hypogonadotropic Hypogonadism From Self-limited Delayed Puberty. The Journal of Clinical Endocrinology & Metabolism, 110(10), e3203-e3214. https://doi.org/10.1210/clinem/dgaf062
Vancouver
Castro S, Correa Brito L, Bedecarrás P, Ballerini MG, Sansó G, Keselman A, et al. FSH and Sertoli Cell Biomarkers Accurately Distinguish Hypogonadotropic Hypogonadism From Self-limited Delayed Puberty. The Journal of Clinical Endocrinology & Metabolism. 2025;110(10):e3203-e3214. doi:10.1210/clinem/dgaf062
BibTeX
@article{Castro2025,
author = {Castro, Sebastián and Correa Brito, Lourdes and Bedecarrás, Patricia and Ballerini, María Gabriela and Sansó, Gabriela and Keselman, Ana and Cassinelli, Hamilton and Arcari, Andrea Josefina and Alonso, Guillermo F and Chan, Yee-Ming and He, Wen and Ropelato, María Gabriela and Bergadá, Ignacio and Cassorla, Fernando and Rey, Rodolfo A and Grinspon, Romina P},
title = {FSH and Sertoli Cell Biomarkers Accurately Distinguish Hypogonadotropic Hypogonadism From Self-limited Delayed Puberty},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {10},
pages = {e3203--e3214},
doi = {10.1210/clinem/dgaf062}
}
EUVIMED